Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection

Gastroenterology Clinics of North America

Volumn 39, Issue 3, 2010, Pages 465-480

  Furuta, Takahisa ^a   Graham, David Y ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CYP2C19; Helicobacter pylori; Intermediate metabolizer; Pharmacogenomics; Poor metabolizer; Proton pump inhibitor; Rapid metabolizer

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RABEPRAZOLE; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DNA POLYMORPHISM; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GENE FREQUENCY; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PHARMACOGENOMICS; POINT MUTATION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PHARMACOGENETICS; PROTON PUMP INHIBITORS; UPPER GASTROINTESTINAL TRACT;

EID: 77957929045     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.08.007     Document Type: Review

References (68)

1. Graham D., Sung J. Helicobacter pylori Sleisenger & Fordtran's gastrointestinal and liver disease. Pathophysiology, diagnosis, management 2006, 1049-1066. WB Saunders Co, Philadelphia. 7th edition. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
2. Marshall B.J., Goodwin C.S., Warren J.R., et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988, 2(8626-8627):1437-1442.
3. Ofman J.J., Etchason J., Fullerton S., et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997, 126(4):280-291.
4. Furuta T., Futami H., Arai H., et al. Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. J Clin Gastroenterol 1995, 20(Suppl 2):S107-S111.
5. Wotherspoon A.C. Helicobacter pylori infection and gastric lymphoma. Br Med Bull 1998, 54(1):79-85.
6. Uemura N., Mukai T., Okamoto S., et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997, 6(8):639-642.
7. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345(11):784-789.
8. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372(9636):392-397.
9. Grayson M.L., Eliopoulos G.M., Ferraro M.J., et al. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989, 8(10):888-889.
10. Scott D., Weeks D., Melchers K., et al. The life and death of Helicobacter pylori. Gut 1998, 43(Suppl 1):S56-S60.
11. Scott D.R., Weeks D., Hong C., et al. The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 1998, 114(1):58-70.
12. Goddard A.F., Jessa M.J., Barrett D.A., et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996, 111(2):358-367.
13. Midolo P.D., Turnidge J.D., Lambert J.R., et al. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrobial Agents Chemother 1996, 40(6):1531-1533.
14. Sim S.C., Risinger C., Dahl M.L., et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006, 79(1):103-113.
15. Kurzawski M., Gawronska-Szklarz B., Wrzesniewska J., et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006, 62(10):877-880.
16. De Morais S.M., Wilkinson G.R., Blaisdell J., et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994, 46(4):594-598.
17. de Morais S.M., Goldstein J.A., Xie H.G., et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995, 58(4):404-411.
18. de Morais S.M., Wilkinson G.R., Blaisdell J., et al. The major genetic defect responsible for the polymorphism of S- mephenytoin metabolism in humans. J Biol Chem 1994, 269(22):15419-15422.
19. Xie H.G., Kim R.B., Stein C.M., et al. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol 1999, 48(3):402-408.
20. Kubota T., Chiba K., Ishizaki T. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996, 60(6):661-666.
21. Xie H.G., Stein C.M., Kim R.B., et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'- hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999, 9(5):539-549.
22. Furuta T., Ohashi K., Kosuge K., et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999, 65(5):552-561.
23. Shirai N., Furuta T., Moriyama Y., et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001, 15(12):1929-1937.
24. Shirai N., Furuta T., Xiao F., et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002, 16(4):837-846.
25. Ferrero J.L., Bopp B.A., Marsh K.C., et al. Metabolism and disposition of clarithromycin in man. Drug Metab Dispos 1990, 18(4):441-446.
26. Chang W.L., Sheu B.S., Cheng H.C., et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009, 24(7):1230-1235.
27. Versalovic J., Shortridge D., Kibler K., et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrobial Agents Chemother 1996, 40(2):477-480.
28. De Francesco V., Margiotta M., Zullo A., et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006, 144(2):94-100.
29. Furuta T., Ohashi K., Kobayashi K., et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999, 66(3):265-274.
30. Wakasugi H., Yano I., Ito T., et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998, 64(1):123-128.
31. Jenks P.J., Edwards D.I. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents 2002, 19(1):1-7.
32. Romano M., Iovene M.R., Russo M.I., et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008, 61(10):1112-1115.
33. Hylek E.M. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med 2001, 17(1):1-13.
34. Wells P.S., Holbrook A.M., Crowther N.R., et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994, 121(9):676-683.
35. Miyachi H., Miki I., Aoyama N., et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006, 11(4):243-249.
36. Di Caro S., Franceschi F., Mariani A., et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009, 41(7):480-485.
37. al-Assi M.T., Ramirez F.C., Lew G.M., et al. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994, 89(8):1203-1205.
38. Egan B.J., Marzio L., O'Connor H., et al. Treatment of Helicobacter pylori infection. Helicobacter 2008, 13(Suppl 1):35-40.
39. Hassan C., De Francesco V., Zullo A., et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 2003, 18(6):641-646.
40. Essa A.S., Kramer J.R., Graham D.Y., et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing " concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009, 14(2):109-118.
41. Furuta T., Ohashi K., Kamata T., et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998, 129(12):1027-1030.
42. Asaka M., Sugiyama T., Kato M., et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001, 6(3):254-261.
43. Andersson T., Miners J.O., Veronese M.E., et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994, 37(6):597-604.
44. Rodrigues A.D., Roberts E.M., Mulford D.J., et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997, 25(5):623-630.
45. Furuta T., Shirai N., Takashima M., et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001, 69(3):158-168.
46. Dojo M., Azuma T., Saito T., et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001, 33(8):671-675.
47. Inaba T., Mizuno M., Kawai K., et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002, 17(7):748-753.
48. Zhao F., Wang J., Yang Y., et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008, 13(6):532-541.
49. Versalovic J., Osato M.S., Spakovsky K., et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 1997, 40(2):283-286.
50. Stone G.G., Shortridge D., Versalovic J., et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrobial Agents Chemother 1997, 41(3):712-714.
51. Menard A., Santos A., Megraud F., et al. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrobial Agents Chemother 2002, 46(4):1156-1157.
52. Furuta T., Sagehashi Y., Shirai N., et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005, 3(6):564-573.
53. Adamek R.J., Suerbaum S., Pfaffenbach B., et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 1998, 93(3):386-389.
54. Bayerdorffer E., Miehlke S., Mannes G.A., et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995, 108(5):1412-1417.
55. Graham D.Y., Lu H., Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008, 68(6):725-736.
56. Graham D.Y., Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008, 5(6):321-331.
57. Furuta T., Shirai N., Xiao F., et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003, 50(54):2274-2278.
58. Furuta T., Shirai N., Takashima M., et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001, 11(4):341-348.
59. Julapalli V.R., Graham D.Y. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci 2005, 50(7):1185-1193.
60. Hunt R.H., Armstrong D., Yaghoobi M., et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008, 28(2):187-199.
61. Tanimura H., Kawano S., Kubo M., et al. Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J Gastroenterol 1998, 33(1):23-26.
62. Furuta T., Shirai N., Kodaira M., et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007, 81(4):521-528.
63. Furuta T., Shirai N., Xiao F., et al. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001, 70(5):484-492.
64. Tanigawara Y., Aoyama N., Kita T., et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999, 66(5):528-534.
65. Sapone A., Vaira D., Trespidi S., et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003, 98(5):1010-1015.
66. Shirai N., Sugimoto M., Kodaira C., et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007, 63(8):743-749.
67. Miehlke S., Kirsch C., Schneider-Brachert W., et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003, 8(4):310-319.
68. Graham D.Y., Javed S.U., Keihanian S., et al. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol 2010, 45(8):816-820.